| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Apixaban versus warfarin in patients with atrial fibrillation.
|
N Engl J Med
|
2011
|
23.50
|
|
2
|
Efficacy and safety of apixaban compared with warfarin at different levels of predicted international normalized ratio control for stroke prevention in atrial fibrillation.
|
Circulation
|
2013
|
3.25
|
|
3
|
The novel biomarker-based ABC (age, biomarkers, clinical history)-bleeding risk score for patients with atrial fibrillation: a derivation and validation study.
|
Lancet
|
2016
|
3.02
|
|
4
|
N-terminal pro-B-type natriuretic peptide for risk assessment in patients with atrial fibrillation: insights from the ARISTOTLE Trial (Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation).
|
J Am Coll Cardiol
|
2013
|
2.90
|
|
5
|
Efficacy and safety of apixaban compared with warfarin according to age for stroke prevention in atrial fibrillation: observations from the ARISTOTLE trial.
|
Eur Heart J
|
2014
|
2.32
|
|
6
|
Apixaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of the ARISTOTLE trial.
|
Lancet Neurol
|
2012
|
1.99
|
|
7
|
Efficacy and safety of apixaban compared with warfarin according to patient risk of stroke and of bleeding in atrial fibrillation: a secondary analysis of a randomised controlled trial.
|
Lancet
|
2012
|
1.83
|
|
8
|
Efficacy and safety of apixaban in patients after cardioversion for atrial fibrillation: insights from the ARISTOTLE Trial (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation).
|
J Am Coll Cardiol
|
2013
|
1.78
|
|
9
|
Growth differentiation factor 15, a marker of oxidative stress and inflammation, for risk assessment in patients with atrial fibrillation: insights from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial.
|
Circulation
|
2014
|
1.65
|
|
10
|
Apixaban 5 mg Twice Daily and Clinical Outcomes in Patients With Atrial Fibrillation and Advanced Age, Low Body Weight, or High Creatinine: A Secondary Analysis of a Randomized Clinical Trial.
|
JAMA Cardiol
|
2016
|
1.43
|
|
11
|
Performance and Validation of a Novel Biomarker-Based Stroke Risk Score for Atrial Fibrillation.
|
Circulation
|
2016
|
1.41
|
|
12
|
Biomarkers of inflammation and risk of cardiovascular events in anticoagulated patients with atrial fibrillation.
|
Heart
|
2016
|
1.41
|
|
13
|
The discovery and development of rivaroxaban, an oral, direct factor Xa inhibitor.
|
Nat Rev Drug Discov
|
2010
|
1.33
|
|
14
|
The ABC (age, biomarkers, clinical history) stroke risk score: a biomarker-based risk score for predicting stroke in atrial fibrillation.
|
Eur Heart J
|
2016
|
1.14
|
|
15
|
Apixaban versus warfarin in patients with atrial fibrillation according to prior warfarin use: results from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation trial.
|
Am Heart J
|
2013
|
1.14
|
|
16
|
Management and clinical outcomes in patients treated with apixaban vs warfarin undergoing procedures.
|
Blood
|
2014
|
1.08
|
|
17
|
New oral anticoagulants may be particularly useful for asian stroke patients.
|
J Stroke
|
2014
|
1.00
|
|
18
|
High-sensitivity troponin I for risk assessment in patients with atrial fibrillation: insights from the Apixaban for Reduction in Stroke and other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial.
|
Circulation
|
2013
|
0.99
|
|
19
|
Clinical outcomes and management associated with major bleeding in patients with atrial fibrillation treated with apixaban or warfarin: insights from the ARISTOTLE trial.
|
Eur Heart J
|
2014
|
0.94
|
|
20
|
Left ventricular systolic dysfunction, heart failure, and the risk of stroke and systemic embolism in patients with atrial fibrillation: insights from the ARISTOTLE trial.
|
Circ Heart Fail
|
2013
|
0.94
|
|
21
|
High-sensitivity troponin T and risk stratification in patients with atrial fibrillation during treatment with apixaban or warfarin.
|
J Am Coll Cardiol
|
2013
|
0.92
|
|
22
|
Documentation of study medication dispensing in a prospective large randomized clinical trial: experiences from the ARISTOTLE Trial.
|
Am Heart J
|
2013
|
0.88
|
|
23
|
Apixaban in Comparison With Warfarin in Patients With Atrial Fibrillation and Valvular Heart Disease: Findings From the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) Trial.
|
Circulation
|
2015
|
0.84
|
|
24
|
New antithrombotic agents--insights from clinical trials.
|
Nat Rev Cardiol
|
2010
|
0.84
|
|
25
|
Economic evaluation of apixaban for the prevention of stroke in non-valvular atrial fibrillation in the Netherlands.
|
PLoS One
|
2014
|
0.82
|
|
26
|
Clinical outcomes in patients with atrial fibrillation according to sex during anticoagulation with apixaban or warfarin: a secondary analysis of a randomized controlled trial.
|
Eur Heart J
|
2015
|
0.79
|
|
27
|
Polypharmacy and effects of apixaban versus warfarin in patients with atrial fibrillation: post hoc analysis of the ARISTOTLE trial.
|
BMJ
|
2016
|
0.79
|
|
28
|
Blood Pressure Control and Risk of Stroke or Systemic Embolism in Patients With Atrial Fibrillation: Results From the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) Trial.
|
J Am Heart Assoc
|
2015
|
0.78
|
|
29
|
Comparison of cardiac troponins I and T measured with high-sensitivity methods for evaluation of prognosis in atrial fibrillation: an ARISTOTLE substudy.
|
Clin Chem
|
2014
|
0.77
|
|
30
|
Secondary stroke prevention strategies for the oldest patients: possibilities and challenges.
|
Drugs Aging
|
2009
|
0.77
|
|
31
|
Use of Direct Oral Anticoagulants in Patients With Atrial Fibrillation and Valvular Heart Lesions.
|
J Am Heart Assoc
|
2016
|
0.77
|
|
32
|
Efficacy and safety of novel anticoagulants compared with established agents.
|
Ther Adv Hematol
|
2011
|
0.77
|
|
33
|
Effect of rivaroxaban versus warfarin on health care costs among nonvalvular atrial fibrillation patients: observations from rivaroxaban users and matched warfarin users.
|
Adv Ther
|
2015
|
0.76
|
|
34
|
Efficacy and Safety of Apixaban Compared With Warfarin in Patients With Atrial Fibrillation and Peripheral Artery Disease: Insights From the ARISTOTLE Trial.
|
J Am Heart Assoc
|
2017
|
0.75
|
|
35
|
Efficacy and Safety of Apixaban Compared With Warfarin in Patients With Atrial Fibrillation in Relation to Renal Function Over Time: Insights From the ARISTOTLE Randomized Clinical Trial.
|
JAMA Cardiol
|
2016
|
0.75
|
|
36
|
Challenges and Treatment for Stroke Prophylaxis in Patients with Atrial Fibrillation in Mexico: A Review.
|
Am J Cardiovasc Drugs
|
2016
|
0.75
|